Jazz Pharmaceuticals plc (JAZZ) said that its Co-Founder, Chairperson and Chief Executive Officer, Bruce Cozadd, plans to retire from his role as Chief Executive Officer upon appointment of the Company's next leader, expected by the end of 2025. Cozadd will continue serving as Chairperson of the Board of Directors.
The Board will commence a formal search process to identify a new Chief Executive Officer, which is anticipated to conclude within 12 months.
Jazz said it remains on track to meet its full year 2024 total revenue guidance of between $4.0 billion and $4.1 billion. Analysts polled by Thomson Reuters expect the company to report revenues of $4.04 billion for fiscal year 2024. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.